Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 8/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6034967 | 0.85 | TGM2 (0.70) | TGM2NPSR1MEN1ALDH1A1KMT2A | |
| SCHEMBL6034350 | 0.82 | TGM2 (0.73) | TGM2MEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL6033401 | 0.82 | TGM2 (1.00) | TGM2 | |
| SCHEMBL6033409 | 0.80 | TGM2 (0.75) | TGM2NPSR1MEN1ALDH1A1KMT2A | |
| SCHEMBL6033954 | 0.75 | TGM2 (0.69) | TGM2 | |
| SCHEMBL6034368 | 0.75 | TGM2 (0.66) | TGM2 | |
| SCHEMBL6034973 | 0.74 | TGM2 (0.71) | TGM2MEN1KMT2A | |
| SCHEMBL6033978 | 0.71 | TGM2 (0.48) | TGM2NPSR1MEN1KMT2AMAPT | |
| SCHEMBL6037625 | 0.69 | TGM2 (1.00) | TGM2NPSR1MEN1ALDH1A1KMT2A | |
| SCHEMBL4146487 | 0.69 | TGM2 (0.51) | TGM2KMT2ASIGMAR1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006060702-A1 | SUBSTITUED 3,4-DIHYDROTHIENO [2,3-D] PYRMIDINES AS TISSUE TRANSGLUTAMINASE INHIBITORS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2006-06-08 | — | — | WO | disclosed |